SG10201909413SA - Method of treating medulloblastoma with an ezh2 inhibitor - Google Patents

Method of treating medulloblastoma with an ezh2 inhibitor

Info

Publication number
SG10201909413SA
SG10201909413SA SG10201909413SA SG10201909413SA SG 10201909413S A SG10201909413S A SG 10201909413SA SG 10201909413S A SG10201909413S A SG 10201909413SA SG 10201909413S A SG10201909413S A SG 10201909413SA
Authority
SG
Singapore
Prior art keywords
ezh2 inhibitor
medulloblastoma
treating
ezh2
inhibitor
Prior art date
Application number
Other languages
English (en)
Inventor
Heike Keilhack
Nigel Waters
Rajeev Vibhakar
Original Assignee
Epizyme Inc
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc, Univ Colorado Regents filed Critical Epizyme Inc
Publication of SG10201909413SA publication Critical patent/SG10201909413SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
SG10201909413S 2015-10-06 2016-10-05 Method of treating medulloblastoma with an ezh2 inhibitor SG10201909413SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562238074P 2015-10-06 2015-10-06
US201662299312P 2016-02-24 2016-02-24

Publications (1)

Publication Number Publication Date
SG10201909413SA true SG10201909413SA (en) 2019-11-28

Family

ID=58488487

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201909413S SG10201909413SA (en) 2015-10-06 2016-10-05 Method of treating medulloblastoma with an ezh2 inhibitor

Country Status (12)

Country Link
US (2) US20190083504A1 (he)
EP (2) EP4309738A3 (he)
JP (1) JP7045985B2 (he)
KR (1) KR20180058829A (he)
CN (1) CN108699046A (he)
AU (3) AU2016333982A1 (he)
CA (1) CA3000983A1 (he)
EA (1) EA201890878A1 (he)
IL (2) IL258510A (he)
MX (1) MX2018004132A (he)
SG (1) SG10201909413SA (he)
WO (1) WO2017062495A2 (he)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
AU2017211331A1 (en) 2016-01-29 2018-06-07 Epizyme, Inc. Combination therapy for treating cancer
CA3025933A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (ja) 2017-06-02 2020-07-30 エピザイム,インコーポレイティド 癌を処置するためのezh2阻害剤の使用
CA3074720A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
WO2020247130A1 (en) * 2019-06-03 2020-12-10 Icahn School Of Medicine At Mount Sinai Compounds and methods for inhibiting cancers via rest inhibition
CN111905102A (zh) * 2020-09-04 2020-11-10 福建医科大学附属第一医院 Ezh2抑制剂在治疗胶质瘤中的应用
KR20230120883A (ko) 2022-02-10 2023-08-17 서울대학교병원 Hsp70을 표적으로 하는 수모세포종 치료 및 전이 억제 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4236945A (en) * 1978-11-27 1980-12-02 Allegheny Ludlum Steel Corporation Phosphorus-iron powder and method of producing soft magnetic material therefrom
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ES2534804T3 (es) * 2010-05-07 2015-04-28 Glaxosmithkline Llc Indazoles
PT2566327T (pt) 2010-05-07 2017-05-26 Glaxosmithkline Llc Indoles
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
PT2908823T (pt) * 2012-10-15 2019-11-04 Epizyme Inc Métodos para tratamento do cancro
TWI629273B (zh) 2013-02-11 2018-07-11 美商星宿藥物公司 甲基修飾酵素之調節劑、其組成物及用途
BR112016012713A2 (pt) * 2013-12-06 2017-08-08 Epizyme Inc Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
JP2018532761A (ja) * 2015-11-06 2018-11-08 エピザイム,インコーポレイティド Ezh2阻害剤を用いた癌の処置のための小児投与

Also Published As

Publication number Publication date
EA201890878A1 (ru) 2018-08-31
IL258510A (he) 2018-05-31
JP7045985B2 (ja) 2022-04-01
KR20180058829A (ko) 2018-06-01
AU2016333982A1 (en) 2018-04-26
EP3371175A4 (en) 2019-09-25
CA3000983A1 (en) 2017-04-13
US20200268765A1 (en) 2020-08-27
MX2018004132A (es) 2018-09-26
EP4309738A2 (en) 2024-01-24
WO2017062495A2 (en) 2017-04-13
WO2017062495A3 (en) 2017-06-08
IL281318A (he) 2021-04-29
EP4309738A3 (en) 2024-07-17
AU2021204331A1 (en) 2021-07-22
CN108699046A (zh) 2018-10-23
JP2018529742A (ja) 2018-10-11
EP3371175A2 (en) 2018-09-12
US20190083504A1 (en) 2019-03-21
AU2023246384A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
SG10201909413SA (en) Method of treating medulloblastoma with an ezh2 inhibitor
EA201790398A1 (ru) Способы лечения заболевания печени
NZ731467A (en) Anti-tim3 antibodies and methods of use
PH12015502075A1 (en) Treatment of cataplexy
MX2016013375A (es) Tratamiento de la hgna y ehna.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
MX2017007095A (es) Metodos y composiciones de activacion de la ligasa parkin.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
PH12017501980A1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
MX2017006022A (es) Inhibicion de ornitina aminotransferasa con analogos gaba para el tratamiento de carcinoma hepatocelular.
MX2017007069A (es) Composiciones con inhibidor selectivo de la trans-señalizacion de il-6.
MX2015008310A (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2017004819A (es) Metodos de tratamiento de transtornos urológicos usando sarm.
MX2017009313A (es) Formulaciones intravenosas de baclofeno y metodos de tratamiento.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
PH12016502284B1 (en) Cough medicine containing ambroxol hydrochloride